Overview

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors. Its objective is to assess the safety, tolerability, and antitumor activity of SSGJ-706 in combination with standard treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Shenyang Sunshine Pharmaceutical Co., LTD.

Treatments:

Capecitabine
Oxaliplatin